Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANEXSIA 7.5/325 vs BRINZOLAMIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrocodone is a mu-opioid receptor agonist, producing analgesia and euphoria. Acetaminophen inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and providing analgesic and antipyretic effects.
Brinzolamide is a carbonic anhydrase inhibitor. It inhibits carbonic anhydrase II (CA-II) in the ciliary processes of the eye, reducing aqueous humor secretion and thereby lowering intraocular pressure.
Management of moderate to moderately severe pain where treatment with an opioid is appropriate and for which alternative treatments are inadequate
Open-angle glaucoma,Ocular hypertension
1 tablet (hydrocodone 7.5 mg / acetaminophen 325 mg) orally every 4 to 6 hours as needed for pain; maximum 6 tablets per day (hydrocodone 45 mg / acetaminophen 1950 mg).
1 drop of 1% solution in the affected eye(s) twice daily.
Hydrocodone: 3.8-4.5 hours (immediate-release). Acetaminophen: 2-3 hours. Clinical note: Half-life prolonged in hepatic impairment; requires dose adjustment.
Terminal elimination half-life: 111 days (due to extensive red blood cell binding); clinical context: steady-state reached after 8–12 weeks of dosing
Hydrocodone: CYP3A4 and CYP2D6; Acetaminophen: primarily via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation, with minor oxidation by CYP2E1.
Primarily metabolized via hepatic cytochrome P450 isoenzymes, including CYP3A4, CYP2A6, CYP2C8, and CYP2C9, to its major metabolite N-desethylbrinzolamide.
Renal: ~90-100% as hydrocodone metabolites (conjugated) and unchanged hydrocodone; ~60% as acetaminophen metabolites (glucuronide, sulfate, cysteine); <5% unchanged acetaminophen. Biliary/fecal: <5%.
Renal: approximately 60% unchanged; biliary/fecal: minimal (<10%)
Hydrocodone: ~20-30% (albumin). Acetaminophen: ~10-25% (albumin).
~60% bound to plasma proteins (primarily albumin, also carbonic anhydrase in RBCs)
Hydrocodone: 3-4 L/kg (extensive tissue distribution). Acetaminophen: ~1 L/kg (uniformly distributed).
0.13–0.25 L/kg (confined primarily to plasma and RBCs; low Vd due to high tissue binding)
Oral: Hydrocodone ~70% (high first-pass metabolism); Acetaminophen ~85-90% (minimal first-pass).
Ophthalmic: systemic bioavailability ~10% (via corneal absorption); oral: not clinically used
For GFR 30-59 m L/min: administer every 6 hours; maximum 4 tablets per day. For GFR 15-29 m L/min: administer every 8 hours; maximum 3 tablets per day. For GFR <15 m L/min: not recommended due to accumulation of metabolites.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For Cr Cl 30-60 m L/min, use with caution; no specific dose adjustment recommended but monitor for metabolic acidosis.
Child-Pugh Class A: no adjustment necessary. Child-Pugh Class B: reduce dose by 25-50% and extend dosing interval to every 6-8 hours; maximum 4 tablets per day. Child-Pugh Class C: contraindicated due to risk of hepatotoxicity.
No specific adjustment required in mild to moderate hepatic impairment (Child-Pugh A, B). Not studied in severe hepatic impairment (Child-Pugh C); use with caution.
Not recommended for pediatric patients; safety and efficacy not established for children under 18 years. For adolescents ≥18 years: adult dosing.
Safety and efficacy not established in pediatric patients (no approved dosing).
Initiate at 1 tablet (hydrocodone 5 mg / acetaminophen 325 mg) every 6 hours as needed; titrate cautiously due to increased sensitivity, decreased renal function, and risk of respiratory depression. Maximum 4 tablets per day.
No specific dose adjustment required; use with caution due to increased risk of corneal edema and metabolic acidosis in elderly patients.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity due to acetaminophen.
None.
Risk of opioid addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use of alcohol, benzodiazepines, or other CNS depressants; hepatotoxicity; severe hypotension; adrenal insufficiency; seizures; GI obstruction; impaired mental/physical abilities; use in elderly, cachectic, or debilitated patients; renal impairment; hepatic impairment; pregnancy; labor and delivery; nursing mothers; pediatric use; driving and operating machinery.
Sulfonamide allergy: can cause serious adverse reactions similar to systemic sulfonamides, including Stevens-Johnson syndrome and toxic epidermal necrolysis.,Corneal endothelial function: use with caution in patients with compromised corneas due to potential for edema.,Bacterial keratitis: risk from contaminated ophthalmic solutions.,Ocular effects: may cause blurred vision, eye discomfort, and other local reactions.,Systemic effects: possible metabolic acidosis, especially in patients with renal impairment or concurrent oral carbonic anhydrase inhibitors.
Significant respiratory depression; acute or severe bronchial asthma; known or suspected GI obstruction; hypersensitivity to hydrocodone or acetaminophen; concomitant use of MAOIs or within 14 days of such therapy.
Hypersensitivity to brinzolamide or any component of the formulation,Severe renal impairment (Cr Cl < 30 m L/min) or hyperchloremic acidosis due to risk of metabolic acidosis,Concomitant use with oral carbonic anhydrase inhibitors (additive systemic effects)
Avoid alcohol consumption due to increased risk of acetaminophen hepatotoxicity and CNS depression. No specific food restrictions, but grapefruit juice may theoretically affect hydrocodone metabolism via CYP3A4 inhibition; however, clinical significance is uncertain.
No direct food interactions. However, brinzolamide may cause metabolic acidosis, so avoid carbonic anhydrase inhibitors (e.g., acetazolamide) and limit sodium bicarbonate intake. No specific dietary restrictions.
FDA Category C (hydrocodone) and Category D (acetaminophen) in third trimester. First trimester: Acetaminophen associated with rare gastroschisis; hydrocodone risk of neural tube defects. Second trimester: No major malformations except with prolonged opioid use. Third trimester: Acetaminophen safe; hydrocodone risk of neonatal opioid withdrawal syndrome (NOWS). Avoid near term.
Brinzolamide is a carbonic anhydrase inhibitor. Limited human data; animal studies show no teratogenicity at clinically relevant doses. Risk cannot be excluded. Avoid in pregnancy unless benefit outweighs risk. First trimester: potential for teratogenic effects unknown; second and third trimesters: possible fetal acidosis due to maternal carbonic anhydrase inhibition.
Hydrocodone/acetaminophen excreted in breast milk. M/P ratio unknown. Hydrocodone relative infant dose <3% of weight-adjusted maternal dose. Acetaminophen relative infant dose <2%. Use with caution; monitor infant for sedation, apnea, poor feeding. Highest risk in CYP2D6 ultrarapid metabolizers.
Excretion in human milk unknown; M/P ratio not available. Due to potential for serious adverse reactions in nursing infants, decision should be made to discontinue nursing or drug. Consider alternative therapy.
Increased clearance of hydrocodone in pregnancy may require dose adjustment; monitor for inadequate analgesia. Acetaminophen pharmacokinetics unchanged. Avoid high doses (hepatotoxicity risk). Consider baseline hepatic function. No specific dose adjustment recommended; titrate to effect.
No pharmacokinetic studies in pregnancy; no dose adjustment recommended. Consider that pregnancy-induced physiologic changes (increased Vd, renal clearance) may reduce drug exposure; monitor clinical response.
ANEXSIA 7.5/325 (hydrocodone/acetaminophen) carries a boxed warning for acetaminophen hepatotoxicity; maximum acetaminophen dose from all sources should not exceed 4 g/day. Hydrocodone is metabolized by CYP2D6 to hydromorphone; ultrarapid metabolizers may experience toxicity. Avoid concurrent use with other CNS depressants including alcohol. Prescribe with caution in patients with renal impairment (hydrocodone accumulation) or hepatic impairment (acetaminophen toxicity). Monitor for signs of respiratory depression, especially at therapy initiation and dose titration. Use the lowest effective dose for the shortest duration.
Brinzolamide is a carbonic anhydrase inhibitor used topically for ocular hypertension. It reduces intraocular pressure by decreasing aqueous humor secretion. Unlike systemic CAIs, it causes fewer systemic side effects but may still cause metabolic acidosis in susceptible patients. Avoid use in patients with sulfonamide allergy due to cross-sensitivity. Monitor corneal endothelial function in patients with compromised corneas. Shake suspension well before use.
Do not exceed 6 tablets per day due to acetaminophen content.,Avoid alcohol while taking this medication.,Do not drive or operate heavy machinery until you know how this medication affects you.,Take exactly as prescribed; do not share with others.,Seek emergency help if you experience difficulty breathing, severe drowsiness, or signs of allergic reaction.,Store securely out of reach of children and dispose of unused medication properly.
Shake the bottle well before each use.,Instill one drop in the affected eye(s) three times daily.,Wash hands before and after administration.,Remove contact lenses before instilling and wait 15 minutes before reinserting.,Do not touch the dropper tip to any surface.,Report any signs of allergy or severe eye discomfort.,May cause temporary blurred vision; avoid driving until clear.
No interactions on record
"Brinzolamide, a carbonic anhydrase inhibitor used for glaucoma, can reduce intraocular pressure and may cause systemic acidosis. Ketoconazole, an azole antifungal, inhibits CYP3A4 and can increase the systemic exposure of drugs metabolized by this enzyme. Although brinzolamide is primarily eliminated renally, co-administration may lead to additive metabolic acidosis, potentially enhancing ketoconazole's toxicity due to altered pH-dependent drug distribution and clearance."
"Olsalazine, a prodrug of mesalamine used for ulcerative colitis, can cause metabolic acidosis via carbonic anhydrase inhibition in the kidney. Brinzolamide, a topical carbonic anhydrase inhibitor for glaucoma, may additively reduce renal bicarbonate reabsorption, increasing the risk of hyperchloremic metabolic acidosis and electrolyte disturbances. Concurrent use may exacerbate acidosis, leading to symptoms like tachypnea, fatigue, and confusion."
"The combination of two carbonic anhydrase inhibitors, Brinzolamide (ophthalmic) and Diclofenamide (systemic), can lead to additive inhibition of carbonic anhydrase in renal tubules, resulting in enhanced systemic absorption and elevated plasma concentrations of Brinzolamide. This may cause severe metabolic acidosis, electrolyte imbalances (e.g., hypokalemia), and increased risk of sulfonamide-related adverse effects such as Stevens-Johnson syndrome. Patients may present with confusion, tachypnea, cardiac arrhythmias, or acute kidney injury."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANEXSIA 7.5/325 vs BRINZOLAMIDE, answered by our medical review team.
ANEXSIA 7.5/325 is a Opioid Analgesic Combination that works by Hydrocodone is a mu-opioid receptor agonist, producing analgesia and euphoria. Acetaminophen inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and providing analgesic and antipyretic effects.. BRINZOLAMIDE is a Carbonic Anhydrase Inhibitor that works by Brinzolamide is a carbonic anhydrase inhibitor. It inhibits carbonic anhydrase II (CA-II) in the ciliary processes of the eye, reducing aqueous humor secretion and thereby lowering intraocular pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANEXSIA 7.5/325 and BRINZOLAMIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANEXSIA 7.5/325 is: 1 tablet (hydrocodone 7.5 mg / acetaminophen 325 mg) orally every 4 to 6 hours as needed for pain; maximum 6 tablets per day (hydrocodone 45 mg / acetaminophen 1950 mg).. The standard adult dose of BRINZOLAMIDE is: 1 drop of 1% solution in the affected eye(s) twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANEXSIA 7.5/325 and BRINZOLAMIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANEXSIA 7.5/325 is classified as Category C. FDA Category C (hydrocodone) and Category D (acetaminophen) in third trimester. First trimester: Acetaminophen associated with rare gastroschisis; hydrocodone risk of neural tube d. BRINZOLAMIDE is classified as Category A/B. Brinzolamide is a carbonic anhydrase inhibitor. Limited human data; animal studies show no teratogenicity at clinically relevant doses. Risk cannot be excluded. Avoid in pregnancy . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.